HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Sankar D. Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W. Johnson, Jonathan C. Craig, Giovanni F.M. Strippoli

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Patients with chronic kidney disease (CKD) are at very high risk of heart disease. Statins have been shown to decrease cholesterol levels and mortality in the general population. The aim of this review was to analyse if a similar effect could be shown in patients with non‐dialysis dependent CKD. This review identified 26 completed studies (25,017 patients). Statins decreased all‐cause mortality and cardiovascular mortality along with lowering lipid levels to an extent which is similar to that found in the general population. Statins also reduce protein excretion in urine but the impact of this on the risk of needing renal replacement therapy needs to be studied further. Statins were not found to have serious adverse effects in this group of people.
Original languageEnglish
Article numberCD007784
Number of pages54
JournalCochrane Database of Systematic Reviews
Issue number2
DOIs
Publication statusPublished - 15 Apr 2009

Keywords

  • kidney disease
  • heart disease
  • Statins

Fingerprint Dive into the research topics of 'HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis'. Together they form a unique fingerprint.

  • Cite this

    Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. M. (2009). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews, (2), [CD007784]. https://doi.org/10.1002/14651858.CD007784